Company Filing History:
Years Active: 2025
Title: Rebekka Krumbach: Innovator in Genetic Therapeutics
Introduction
Rebekka Krumbach is a prominent inventor based in Boston, MA, known for her significant contributions to the field of genetic therapeutics. She has developed innovative solutions aimed at addressing genetic disorders, particularly those related to the ABCA4 gene.
Latest Patents
Rebekka holds a patent for her work on ABCA4 trans-splicing molecules. This patent describes nucleic acid trans-splicing molecules, including pre-mRNA trans-splicing molecules and RNA exon editing molecules, which are capable of correcting mutations in the ABCA4 gene. These advancements are particularly useful in treating disorders such as ABCA4-associated retinal dystrophies, including Stargardt Disease and cone-rod dystrophy. The patent also outlines methods for utilizing these molecules to correct mutations in ABCA4, thereby providing therapeutic options for affected individuals.
Career Highlights
Rebekka is currently associated with Ascidian Therapeutics, Inc., where she continues to advance her research and development efforts in genetic therapies. Her work is pivotal in the ongoing quest to find effective treatments for genetic disorders.
Collaborations
Rebekka collaborates with esteemed colleagues, including Scott J. Dooley and Akiko Doi, to further enhance the impact of her research in the field of genetic therapeutics.
Conclusion
Rebekka Krumbach's innovative work in developing ABCA4 trans-splicing molecules represents a significant advancement in the treatment of genetic disorders. Her contributions are paving the way for new therapeutic strategies that could improve the lives of many individuals affected by these conditions.